Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lysosomal Hydrolases01:22

Lysosomal Hydrolases

4.0K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.0K
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

254
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
254
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

447
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
447
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

302
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
302
Parkinson's Disease: Overview01:15

Parkinson's Disease: Overview

854
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
854
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

143
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
143

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

From dysbiosis to malignancy: decoding gut-driven pathways to clinical management in hepatocellular carcinoma.

Frontiers in cellular and infection microbiology·2026
Same author

The DICA endoscopic score and the CODA clinical score may predict the severity of acute diverticulitis and the risk of hospitalisation: results from an international multicentre prospective cohort study.

Techniques in coloproctology·2026
Same author

Can ammonia scavenging treat MASLD? Evaluating the evidence for L-ornithine L-aspartate-A systematic review.

European journal of clinical investigation·2026
Same author

When the Liver Echoes to the Heart: Assessing Subclinical Cardiac Dysfunction in NAFLD Using Speckle Tracking Echocardiography-A Systematic Review and Meta-Analysis.

Biomedicines·2025
Same author

Therapeutic strategies for the prevention of acute diverticulitis according to the Diverticular Inflammation and Complication Assessment endoscopic score: a post hoc analysis of a prospective international study.

European journal of gastroenterology & hepatology·2025
Same author

Metabolic Dysfunction-Associated Steatohepatitis in Focus: Pathogenesis, Non-Invasive Diagnostics, and Future Approaches.

Archives of medical research·2025

Related Experiment Video

Updated: Oct 20, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.2K

Gaucher disease: an update.

Dan L Dumitrascu1

  • 12Department of Internal Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania.

Medicine and Pharmacy Reports
|September 16, 2021
PubMed
Summary

Gaucher disease is a rare genetic disorder impacting multiple organs. Early diagnosis and optimal therapy are crucial for managing this lysosomal storage disease in adult patients.

Area of Science:

  • Medical Genetics
  • Biochemistry
  • Hematology

Background:

  • Gaucher disease is a rare, inherited lysosomal storage disorder.
  • It affects multiple organs, including bone marrow, spleen, liver, and the nervous system.
  • Over 70 adult patients with Gaucher disease are monitored in Romania, receiving fully covered therapy.

Purpose of the Study:

  • To review recent studies on Gaucher disease.
  • To highlight the importance of early screening and diagnosis.
  • To discuss the optimal therapeutic strategies for Gaucher disease.

Main Methods:

  • Literature review of recent studies on Gaucher disease.
  • Analysis of current patient management and therapeutic approaches.
  • Focus on screening and early diagnostic methods.
Keywords:
Gaucher diseaseenzyme replacing therapylysosomal diseasestorage diseasesubstrate reducing therapy

More Related Videos

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.0K
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

12.2K

Related Experiment Videos

Last Updated: Oct 20, 2025

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
10:16

In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease

Published on: December 20, 2017

8.2K
An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy
07:45

An In Vitro Model for the Study of Cellular Pathophysiology in Globoid Cell Leukodystrophy

Published on: October 21, 2014

8.0K
Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration
07:46

Gait Analysis of Age-dependent Motor Impairments in Mice with Neurodegeneration

Published on: June 18, 2018

12.2K

Main Results:

  • Gaucher disease requires ongoing monitoring and timely intervention.
  • Effective therapies are available and covered for patients in Romania.
  • Early detection significantly improves patient outcomes.

Conclusions:

  • There is a critical need for widespread screening and early diagnosis of Gaucher disease.
  • Optimal and accessible therapy is vital for managing Gaucher disease.
  • This review serves as a resource for medical trainees managing Gaucher disease.